Next Article in Journal
Autoimmune Syndromes Presenting as a Paraneoplastic Manifestation of Myelodysplastic Syndromes: Clinical Features, Course, Treatment and Outcome
Previous Article in Journal
Presentation and Management of Paroxysmal Nocturnal Hemoglobinuria: A Single-Center Experience
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 8
Issue 2
10.4081/hr.2016.6417
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Recurrent Syncope and Cardiac Arrest in a Patient with Systemic Light Chain Amyloidosis Treated with Bortezomib

by
Navin Jaipaul
1,2,*,
Alexander Pi
2 and
Zhiwei Zhang
1,2
1
VA Loma Linda Healthcare System, 11201 Benton St. (111N), Loma Linda, CA 92357, USA
2
Loma Linda University School of Medicine, Loma Linda, CA, USA
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2016, 8(2), 6417; https://doi.org/10.4081/hr.2016.6417
Submission received: 17 January 2016 / Revised: 16 April 2016 / Accepted: 18 April 2016 / Published: 10 May 2016

Abstract

About 10–15% of patients with multiple myeloma develop light chain (AL) amyloidosis. AL amyloidosis is a systemic disease that may involve multiple organs, often including the heart. It may present clinically with bradyarrhythmia and syncope. The proteasome inhibitor bortezomib has been used with clinical efficacy in treating patients with AL amyloidosis but also implicated as a possible cause of cardiomyocyte injury. We report a case of a 48-year-old man with AL amyloidosis and increased frequency of syncope and cardiac arrest after starting bortezomib. The biologic and clinical plausibility of a heightened risk for cardiac arrest in patients with cardiac AL amyloidosis and history of syncope being treated with bortezomib is a possibility that is not well documented in the medical literature and warrants further investigation.
Keywords: light chain amyloidosis; bortezomib; syncope; cardiac arrest light chain amyloidosis; bortezomib; syncope; cardiac arrest

Share and Cite

MDPI and ACS Style

Jaipaul, N.; Pi, A.; Zhang, Z. Recurrent Syncope and Cardiac Arrest in a Patient with Systemic Light Chain Amyloidosis Treated with Bortezomib. Hematol. Rep. 2016, 8, 6417. https://doi.org/10.4081/hr.2016.6417

AMA Style

Jaipaul N, Pi A, Zhang Z. Recurrent Syncope and Cardiac Arrest in a Patient with Systemic Light Chain Amyloidosis Treated with Bortezomib. Hematology Reports. 2016; 8(2):6417. https://doi.org/10.4081/hr.2016.6417

Chicago/Turabian Style

Jaipaul, Navin, Alexander Pi, and Zhiwei Zhang. 2016. "Recurrent Syncope and Cardiac Arrest in a Patient with Systemic Light Chain Amyloidosis Treated with Bortezomib" Hematology Reports 8, no. 2: 6417. https://doi.org/10.4081/hr.2016.6417

APA Style

Jaipaul, N., Pi, A., & Zhang, Z. (2016). Recurrent Syncope and Cardiac Arrest in a Patient with Systemic Light Chain Amyloidosis Treated with Bortezomib. Hematology Reports, 8(2), 6417. https://doi.org/10.4081/hr.2016.6417

Article Metrics

Back to TopTop